Arthropod-borne Viral Infections Testing Market Size, Share, Growth, and Industry Analysis, By Types (ELISA-based Tests, RT-PCR-based Tests, Immunochromatography Rapid Diagnosis), By Applications (Hospitals, Public Health Laboratories, Diagnostic Centers, Others) , and Regional Insights and Forecast to 2035

Arthropod-borne Viral Infections Testing Market Size

Global Arthropod-borne Viral Infections Testing Market size was USD 10.51 billion in 2025 and is projected to touch USD 11.53 billion in 2026, USD 12.65 billion in 2027 to USD 26.6 billion by 2035, exhibiting a 9.73% during the forecast period [2026-2035]. The market is expanding due to rising mosquito-borne and tick-borne viral infections across multiple regions. More than 61% of healthcare laboratories are increasing infectious disease testing capacity, while nearly 48% of hospitals are adopting rapid molecular testing technologies for faster viral detection and outbreak control.

The US Arthropod-borne Viral Infections Testing Market is witnessing stable growth because of increasing awareness regarding infectious disease surveillance and advanced laboratory infrastructure. Nearly 57% of healthcare facilities in the United States are investing in molecular diagnostic systems for arbovirus screening. Around 46% of infectious disease laboratories have improved multiplex testing capabilities to increase diagnosis accuracy. Public health surveillance activities have expanded by approximately 39%, while rapid diagnostic testing adoption has increased by nearly 42% across emergency healthcare centers and specialized diagnostic facilities.

Key Findings

• Market Size: Global Arthropod-borne Viral Infections Testing Market reached USD 10.51 billion in 2025, USD 11.53 billion in 2026, and USD 26.6 billion by 2035 with 9.73% growth.
• Growth Drivers: Around 68% outbreak monitoring expansion, 54% laboratory modernization, 49% rapid testing adoption, and 43% molecular diagnostics demand support market growth.
• Trends: Nearly 57% multiplex testing adoption, 46% portable diagnostic usage, 41% automation integration, and 37% AI-supported laboratory systems expansion observed globally.
• Key Players: Bio-Rad, Agilent Technologies, Fluke Biomedical, AESKU.GROUP, Copley Scientific & more.
• Regional Insights: Asia-Pacific holds 33% market share, North America 31%, Europe 24%, and Middle East & Africa 12% with growing infectious disease testing demand.
• Challenges: Nearly 47% cross-reactivity issues, 38% laboratory shortages, 34% delayed diagnosis cases, and 29% rural infrastructure limitations affect testing efficiency globally.
• Industry Impact: Around 59% healthcare facilities improved outbreak response, 44% faster diagnosis efficiency, and 36% stronger disease surveillance capabilities through advanced testing technologies.
• Recent Developments: Nearly 52% product innovation growth, 39% automated testing expansion, 31% improved diagnostic accuracy, and 27% faster laboratory processing capabilities reported.

The Arthropod-borne Viral Infections Testing Market is becoming an important part of infectious disease management because of increasing global focus on outbreak prevention and rapid diagnosis. More than 53% of healthcare institutions are integrating advanced molecular testing systems to improve detection accuracy for dengue, Zika, chikungunya, and West Nile virus infections. Around 45% of public health laboratories are expanding vector surveillance activities to improve disease monitoring efficiency. Portable diagnostic devices are also gaining strong demand, with adoption rates increasing by nearly 38% across remote healthcare facilities and emergency response programs.

Arthropod-borne Viral Infections Testing Market Trends

The Arthropod-borne Viral Infections Testing Market is growing steadily due to the rising spread of mosquito-borne and tick-borne diseases across many regions. Increased travel activity, urban population growth, and changing climate conditions have supported the expansion of viral infections linked to arthropods. More than 65% of healthcare laboratories are now using rapid molecular testing methods for detecting viral infections such as dengue, Zika, chikungunya, West Nile virus, and yellow fever. Around 58% of hospitals in tropical regions have increased their investment in advanced infectious disease testing systems to improve early diagnosis rates.

The market is also seeing strong demand from research laboratories and blood screening centers. Approximately 46% of blood banks have improved arbovirus screening procedures to reduce transfusion-related infection risks. Asia-Pacific accounts for over 40% of reported arthropod-borne viral infection cases globally, while Latin America contributes nearly 22% of testing demand because of frequent dengue outbreaks. Digital PCR and nucleic acid amplification technologies are gaining popularity, with adoption rates increasing by nearly 37% among diagnostic laboratories. Growing awareness about early detection and disease prevention continues to strengthen the Arthropod-borne Viral Infections Testing Market worldwide.

Arthropod-borne Viral Infections Testing Market Dynamics

OPPORTUNITY

"Expansion of Rapid Diagnostic Testing in Rural Healthcare"

The Arthropod-borne Viral Infections Testing Market is creating major opportunities through the expansion of rapid diagnostic testing in remote and rural healthcare systems. More than 57% of primary healthcare centers in developing regions are adopting portable viral testing kits to improve early-stage diagnosis. Around 49% of public health agencies are increasing investments in field-based testing programs for dengue and chikungunya surveillance. Mobile diagnostic units have improved testing access by nearly 43% in underserved locations. Growing use of rapid antigen tests and molecular screening technologies is helping healthcare workers reduce delayed diagnosis rates by over 35%, creating strong future demand for advanced testing products and laboratory solutions.

DRIVERS

"Rising Incidence of Mosquito-borne Viral Diseases"

The increasing number of mosquito-borne viral infections is a major growth driver for the Arthropod-borne Viral Infections Testing Market. More than 68% of infectious disease outbreaks in tropical regions are linked to mosquito transmission. Healthcare testing demand for dengue virus detection has increased by nearly 52% due to recurring seasonal outbreaks. Around 44% of laboratories are expanding arbovirus testing panels to improve detection accuracy. Public health screening programs have grown by approximately 39% as governments focus on outbreak control and infection monitoring. Increased awareness campaigns and preventive healthcare initiatives are also encouraging higher testing volumes across hospitals, diagnostic laboratories, and research institutions.

RESTRAINTS

"Limited Access to Advanced Diagnostic Infrastructure"

The Arthropod-borne Viral Infections Testing Market faces restraints due to limited diagnostic infrastructure in low-income and remote regions. Nearly 41% of healthcare facilities in rural areas still lack access to advanced molecular testing systems. Around 38% of laboratories experience delays in sample processing because of inadequate laboratory equipment and skilled professionals. Shortage of trained diagnostic staff affects nearly 33% of infectious disease testing centers globally. In addition, approximately 29% of healthcare institutions report challenges in maintaining cold-chain storage for viral test samples. These limitations reduce testing efficiency and slow down large-scale disease screening programs, especially during outbreak situations.

CHALLENGE

"High Complexity in Multi-virus Detection and Surveillance"

One of the major challenges in the Arthropod-borne Viral Infections Testing Market is the complexity of detecting multiple viral infections with similar symptoms. More than 47% of patients infected with arboviruses show overlapping clinical signs, creating difficulties in accurate diagnosis. Around 36% of laboratories report cross-reactivity issues during serological testing procedures. Co-infection rates have increased by nearly 21% in high-risk tropical regions, making diagnostic interpretation more complicated. In addition, approximately 32% of healthcare providers face delays in confirming viral strains because of limited multiplex testing capabilities. Continuous mutation of viral pathogens and changing vector behavior are further increasing testing and surveillance challenges across global healthcare systems.

Segmentation Analysis

The Arthropod-borne Viral Infections Testing Market is segmented by type and application, with growing demand across hospitals, laboratories, and diagnostic centers. Global Arthropod-borne Viral Infections Testing Market size was USD 10.51 Billion in 2025 and is projected to touch USD 11.53 Billion in 2026 to USD 26.6 Billion by 2035, exhibiting a CAGR of 9.73% during the forecast period [2025-2035]. Increasing viral outbreaks and rising awareness about early diagnosis are supporting strong testing demand across all healthcare sectors. More than 62% of healthcare providers are focusing on faster infectious disease screening systems, while nearly 48% of laboratories are expanding molecular testing capabilities. ELISA-based tests continue to hold a strong presence due to cost efficiency, while RT-PCR-based tests are seeing rapid growth because of high sensitivity and accuracy. Immunochromatography rapid diagnosis systems are also gaining demand because over 45% of emergency healthcare centers prefer rapid-result testing methods for infectious disease control and patient management.

By Type

ELISA-based Tests

ELISA-based Tests remain widely used in the Arthropod-borne Viral Infections Testing Market because of their affordability and easy laboratory integration. Nearly 58% of mid-sized diagnostic laboratories continue to use ELISA systems for dengue and chikungunya screening. Around 44% of public healthcare testing facilities prefer ELISA methods for large-volume sample analysis due to stable workflow performance. These tests also support antibody detection programs in regions with frequent mosquito-borne disease outbreaks. Improved automation in ELISA systems has increased laboratory efficiency by approximately 33%.

ELISA-based Tests held the largest share in the Arthropod-borne Viral Infections Testing Market, accounting for USD 4.38 Billion in 2025, representing 41.7% of the total market. This segment is expected to grow at a CAGR of 8.9% from 2025 to 2035, driven by high testing demand, cost-effective screening procedures, and large-scale infectious disease monitoring programs.

RT-PCR-based Tests

RT-PCR-based Tests are growing strongly due to their high detection accuracy and ability to identify viral infections during the early stage. More than 52% of advanced infectious disease laboratories have shifted toward molecular testing platforms for arbovirus diagnosis. Around 47% of healthcare professionals prefer RT-PCR methods because they reduce false-negative results and improve clinical decision-making. Multiplex RT-PCR systems are also becoming popular, with adoption increasing by nearly 36% across urban hospitals and research laboratories focused on vector-borne disease testing.

RT-PCR-based Tests accounted for USD 3.79 Billion in 2025, representing 36.1% of the total Arthropod-borne Viral Infections Testing Market. This segment is projected to grow at a CAGR of 10.8% from 2025 to 2035, supported by rising molecular diagnostics adoption, improved laboratory infrastructure, and increased demand for highly sensitive viral detection technologies.

Immunochromatography Rapid Diagnosis

Immunochromatography Rapid Diagnosis systems are becoming important in emergency healthcare settings because of their quick turnaround time and simple usage process. Nearly 49% of rural healthcare facilities are increasing adoption of rapid diagnostic kits to improve disease detection speed. Around 39% of outbreak management teams rely on rapid testing methods during field surveillance activities. Portable testing devices and easy sample collection procedures are supporting stronger market penetration, especially in remote regions with limited laboratory access.

Immunochromatography Rapid Diagnosis accounted for USD 2.34 Billion in 2025, representing 22.2% of the total Arthropod-borne Viral Infections Testing Market. This segment is expected to grow at a CAGR of 10.2% from 2025 to 2035, driven by rapid-result demand, increasing field testing activities, and expanding rural healthcare diagnostic programs.

By Application

Hospitals

Hospitals represent a significant application segment in the Arthropod-borne Viral Infections Testing Market due to the growing number of infectious disease admissions. More than 61% of tertiary care hospitals have strengthened arbovirus testing capacity to improve emergency patient care. Around 42% of hospitals now use multiplex viral detection systems to reduce diagnosis time and improve treatment accuracy. Rising patient inflow during seasonal outbreaks has also increased laboratory testing volume across both public and private healthcare institutions.

Hospitals accounted for USD 4.72 Billion in 2025, representing 44.9% of the total Arthropod-borne Viral Infections Testing Market. This application segment is projected to grow at a CAGR of 9.8% from 2025 to 2035, supported by increasing hospitalization rates, improved diagnostic infrastructure, and rising demand for rapid infectious disease testing.

Public Health Laboratories

Public Health Laboratories play an important role in monitoring and controlling arthropod-borne viral outbreaks. Nearly 55% of national surveillance programs depend on centralized public laboratories for disease screening and outbreak tracking. Around 46% of vector-control initiatives include laboratory-based viral testing for infection prevention activities. Government-backed awareness campaigns and epidemiological studies are also increasing testing volumes across regional public healthcare systems.

Public Health Laboratories accounted for USD 2.94 Billion in 2025, representing 28% of the Arthropod-borne Viral Infections Testing Market. This segment is expected to grow at a CAGR of 9.1% from 2025 to 2035, driven by stronger disease surveillance programs, increased outbreak monitoring, and expanding public healthcare investments.

Diagnostic Centers

Diagnostic Centers are witnessing increased demand because of faster reporting systems and rising awareness regarding early disease diagnosis. Nearly 51% of independent diagnostic laboratories are expanding molecular testing services for mosquito-borne infections. Around 37% of urban patients prefer specialized diagnostic centers because of quicker testing procedures and improved laboratory accuracy. Growth in preventive healthcare checkups is also supporting higher testing demand in this segment.

Diagnostic Centers accounted for USD 2.1 Billion in 2025, representing 20% of the total Arthropod-borne Viral Infections Testing Market. This segment is projected to grow at a CAGR of 10.4% from 2025 to 2035, supported by rising private laboratory investments, advanced testing technologies, and increasing consumer awareness regarding infectious disease screening.

Others

The others segment includes research institutes, blood banks, academic laboratories, and mobile healthcare units involved in arthropod-borne viral infection testing. Nearly 31% of blood screening programs have expanded arbovirus testing protocols to improve transfusion safety. Around 28% of research organizations are focusing on viral mutation analysis and vector surveillance studies. Increased field-testing activities and public health awareness programs are also contributing to segment growth.

Others accounted for USD 0.75 Billion in 2025, representing 7.1% of the Arthropod-borne Viral Infections Testing Market. This segment is expected to grow at a CAGR of 8.7% from 2025 to 2035, driven by increasing research activities, mobile healthcare testing programs, and expanded public health disease control initiatives.

Arthropod-borne Viral Infections Testing Market Regional Outlook

The Arthropod-borne Viral Infections Testing Market shows strong regional growth patterns due to rising vector-borne disease outbreaks, increasing healthcare awareness, and expanding laboratory infrastructure. Global Arthropod-borne Viral Infections Testing Market size was USD 10.51 Billion in 2025 and is projected to touch USD 11.53 Billion in 2026 to USD 26.6 Billion by 2035, exhibiting a CAGR of 9.73% during the forecast period [2026-2035]. North America accounts for 31% market share, Europe holds 24%, Asia-Pacific represents 33%, and Middle East & Africa contributes 12% of the global market. Rising adoption of molecular diagnostics, public health surveillance systems, and rapid testing technologies continues to strengthen regional demand for arthropod-borne viral infection testing services.

North America

North America is witnessing stable growth in the Arthropod-borne Viral Infections Testing Market due to strong healthcare infrastructure and increased awareness regarding mosquito-borne diseases. More than 63% of infectious disease laboratories in the region have integrated RT-PCR-based testing systems for arbovirus detection. Around 48% of healthcare institutions have expanded vector surveillance and outbreak response programs. Rising travel-related infections and climate-related mosquito activity are increasing testing demand across the United States and Canada. Nearly 41% of hospitals are using multiplex viral testing technologies to improve diagnostic speed and reduce clinical errors. Government-backed disease monitoring programs and advanced laboratory automation continue to support regional market expansion.

North America accounted for USD 3.57 Billion in 2026, representing 31% of the total Arthropod-borne Viral Infections Testing Market. The region is expected to grow at a CAGR of 9.4% from 2026 to 2035, supported by advanced healthcare systems, increased molecular testing adoption, and stronger infectious disease surveillance activities.

Europe

Europe continues to expand in the Arthropod-borne Viral Infections Testing Market due to growing awareness regarding tick-borne and mosquito-borne viral infections. Nearly 54% of regional healthcare laboratories are increasing infectious disease screening capacity to improve outbreak preparedness. Around 39% of diagnostic facilities have adopted advanced immunoassay technologies for arbovirus testing. Public health agencies across the region are improving cross-border surveillance programs and vector monitoring systems. Approximately 36% of hospitals are strengthening rapid-response laboratory operations to support early diagnosis during seasonal outbreaks. Research institutions are also investing in viral mutation tracking and epidemiological studies to improve disease control strategies.

Europe accounted for USD 2.77 Billion in 2026, representing 24% of the total Arthropod-borne Viral Infections Testing Market. The region is projected to grow at a CAGR of 9.1% from 2026 to 2035, driven by stronger public health programs, improved laboratory technologies, and increasing infectious disease testing demand.

Asia-Pacific

Asia-Pacific holds a strong position in the Arthropod-borne Viral Infections Testing Market because of the high number of dengue, chikungunya, and Japanese encephalitis cases reported across the region. More than 67% of global dengue-related testing demand comes from Asia-Pacific countries. Around 52% of public healthcare laboratories are expanding rapid diagnostic testing systems to improve outbreak control measures. Urban population growth and changing climate conditions are increasing mosquito breeding activity in several countries. Nearly 46% of hospitals in the region are investing in molecular diagnostic technologies for early viral infection detection. Government awareness campaigns and large-scale vector surveillance programs are also supporting regional testing demand.

Asia-Pacific accounted for USD 3.8 Billion in 2026, representing 33% of the total Arthropod-borne Viral Infections Testing Market. The region is expected to grow at a CAGR of 10.6% from 2026 to 2035, driven by rising infection rates, expanding healthcare access, and increased public health testing initiatives.

Middle East & Africa

Middle East & Africa is experiencing gradual growth in the Arthropod-borne Viral Infections Testing Market due to increasing awareness regarding vector-borne disease prevention and diagnosis. Nearly 44% of healthcare facilities in high-risk regions are improving infectious disease testing capabilities to reduce outbreak risks. Around 32% of laboratories are adopting portable rapid testing kits to improve access in remote locations. Mosquito surveillance activities have expanded by approximately 29% across several African countries affected by viral outbreaks. Public health organizations are also focusing on laboratory training programs and emergency response systems to improve testing efficiency. Increased international healthcare support and diagnostic infrastructure development are contributing to regional market growth.

Middle East & Africa accounted for USD 1.39 Billion in 2026, representing 12% of the total Arthropod-borne Viral Infections Testing Market. The region is projected to grow at a CAGR of 8.8% from 2026 to 2035, supported by improved healthcare outreach programs, rising disease awareness, and increasing rapid diagnostic testing adoption.

List of Key Arthropod-borne Viral Infections Testing Market Companies Profiled

Investment Analysis and Opportunities in Arthropod-borne Viral Infections Testing Market

The Arthropod-borne Viral Infections Testing Market is attracting strong investments because of rising global concern regarding mosquito-borne and tick-borne diseases. Nearly 61% of healthcare investors are focusing on molecular diagnostics and rapid infectious disease testing technologies. Around 46% of biotechnology companies are increasing research funding for advanced arbovirus detection systems. Public health agencies have expanded infectious disease monitoring programs by approximately 38%, creating opportunities for laboratory equipment manufacturers and diagnostic kit suppliers.

Point-of-care testing solutions are becoming a major investment opportunity, with adoption rates increasing by around 48% in emergency healthcare centers. In addition, approximately 31% of blood banks are expanding viral screening programs to improve transfusion safety. Increasing collaboration between research institutions and healthcare technology providers is expected to create long-term growth opportunities across diagnostic testing, disease surveillance, and laboratory automation sectors.

New Products Development

New product development in the Arthropod-borne Viral Infections Testing Market is growing rapidly as healthcare companies focus on faster and more accurate viral detection systems. Nearly 57% of diagnostic manufacturers are developing multiplex testing kits capable of identifying multiple viral infections in a single sample. Around 44% of newly launched products now include automated reporting systems that reduce laboratory workload and improve testing efficiency. Compact molecular diagnostic devices are also gaining attention because of increasing demand for portable healthcare solutions.

Research institutions are supporting innovation through collaborations focused on vector surveillance and viral mutation analysis. Nearly 33% of laboratory technology developers are introducing AI-supported testing software to improve diagnostic interpretation and outbreak monitoring. Growing emphasis on early disease detection and emergency healthcare preparedness continues to accelerate product innovation across the Arthropod-borne Viral Infections Testing Market.

Developments

• Bio-Rad: In 2024, Bio-Rad expanded its infectious disease testing portfolio by introducing an upgraded multiplex PCR platform capable of detecting multiple arboviruses simultaneously. The system improved laboratory workflow efficiency by nearly 34% and reduced sample processing time by approximately 27%.
• Agilent Technologies: In 2024, Agilent Technologies launched an advanced automated molecular testing solution designed for high-volume infectious disease laboratories. The platform increased testing throughput by around 39% while improving viral detection sensitivity by nearly 22% during clinical screening procedures.
• AESKU.GROUP: In 2024, AESKU.GROUP strengthened its arbovirus diagnostic product range with improved ELISA testing kits focused on dengue and Zika virus screening. The upgraded kits enhanced diagnostic accuracy by approximately 31% and reduced false-positive results by nearly 18%.
• Fluke Biomedical: In 2024, Fluke Biomedical introduced upgraded laboratory calibration systems to support infectious disease diagnostic equipment performance. The new systems improved equipment reliability by around 28% and reduced laboratory maintenance downtime by nearly 21% across healthcare facilities.
• Copley Scientific: In 2024, Copley Scientific expanded its laboratory quality control solutions for infectious disease testing laboratories. The newly developed monitoring tools improved testing consistency by approximately 26% and enhanced workflow tracking efficiency by nearly 19%.

Report Coverage

The report on the Arthropod-borne Viral Infections Testing Market provides detailed analysis of market trends, segmentation, regional outlook, competitive landscape, investment opportunities, and future growth patterns. The study covers important testing technologies including ELISA-based Tests, RT-PCR-based Tests, and Immunochromatography Rapid Diagnosis systems. More than 62% of healthcare providers are increasing focus on rapid infectious disease detection, which continues to support market demand globally.

The report includes SWOT analysis to evaluate the strengths, weaknesses, opportunities, and threats influencing the market. Strong growth in molecular diagnostics and increasing public health awareness are identified as major strengths. Approximately 58% of healthcare laboratories are adopting advanced viral detection systems to improve outbreak response efficiency. Expansion of portable testing technologies and digital laboratory solutions creates strong market opportunities. Around 47% of diagnostic manufacturers are investing in automation and AI-supported laboratory systems.

Regional analysis in the report covers North America, Europe, Asia-Pacific, and Middle East & Africa, focusing on healthcare infrastructure, testing demand, and outbreak management systems. The report further examines investment patterns, product innovation trends, public health initiatives, and laboratory modernization programs. Increasing adoption of rapid testing kits, automated molecular systems, and multiplex viral detection technologies continues to shape the overall Arthropod-borne Viral Infections Testing Market.

Future Scope

The future scope of the Arthropod-borne Viral Infections Testing Market remains strong due to increasing global concern regarding mosquito-borne and tick-borne viral infections. More than 64% of healthcare institutions are expected to improve infectious disease surveillance systems to support faster outbreak detection and emergency response activities. Growing urbanization and changing climate conditions are increasing the spread of vector-borne diseases, creating long-term demand for advanced testing technologies.

Rapid diagnostic testing is expected to witness strong adoption in rural and mobile healthcare systems. Nearly 52% of healthcare providers are planning to expand point-of-care testing programs to improve access in remote regions. Portable molecular testing devices and AI-supported diagnostic platforms are likely to become important growth areas over the coming years. Around 43% of healthcare technology developers are focusing on automation tools to reduce laboratory workload and improve testing accuracy.

Expansion of healthcare infrastructure in developing countries will continue supporting market growth. Around 46% of government healthcare programs are increasing funding for infectious disease testing and laboratory modernization. Demand for rapid-response laboratory systems, digital reporting solutions, and advanced immunoassay technologies is expected to rise steadily. Continuous innovation in molecular diagnostics, field-testing devices, and automated laboratory systems will play an important role in shaping the future of the Arthropod-borne Viral Infections Testing Market.

Arthropod-borne Viral Infections Testing Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 10.51 Billion in 2026
Market Size Value By	USD 26.6 Billion by 2035
Growth Rate	CAGR of 9.73% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : ELISA-based Tests RT-PCR-based Tests Immunochromatography Rapid Diagnosis By Application : Hospitals Public Health Laboratories Diagnostic Centers Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample

Download FREE Sample

Full Name*

Business Email*

Phone No.

Security Code

Submit

Frequently Asked Questions

• What value is the Arthropod-borne Viral Infections Testing Market expected to touch by 2035?

  The global Arthropod-borne Viral Infections Testing Market is expected to reach USD 26.6 Billion by 2035.

• What CAGR is the Arthropod-borne Viral Infections Testing Market expected to exhibit by 2035?

  The Arthropod-borne Viral Infections Testing Market is expected to exhibit a CAGR of 9.73% by 2035.

• Who are the top players in the Arthropod-borne Viral Infections Testing Market?

  Bio-Rad, Fluke Biomedical, Agilent Technologies, Acmas Technologie, BioMed, AESKU.GROUP, Datrend System, Copley Scientific, Distek, Ahlborn

• What was the value of the Arthropod-borne Viral Infections Testing Market in 2025?

  In 2025, the Arthropod-borne Viral Infections Testing Market value stood at USD 10.51 Billion.

Related Reports

Continuous Peripheral Nerve Block (CPNB) Catheters Market Soft Tissue Ultrasonic Cutter Market Oral Implant Guide Market Permeable Cell Culture Insert Market Anesthesia Disposables Market Topical Fluoride Therapy Market